Wedekind, Dirk

Treatment of anxiety disorders

Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychological Treatments and Disorders

Cited by 811

Efficacy of treatments for anxiety disorders: a meta-analysis

Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychotherapy Techniques and Applications

Cited by 555

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., Cinosi, E., Davies, S., Domschke, K., Fineberg, N., et al. (2017) · The World Journal of Biological Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on Behavior

Cited by 347

Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders

Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Rüther, E. (2007) · The World Journal of Biological Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychotherapy Techniques and Applications

Cited by 166

Borderline personality disorder: a dysregulation of the endogenous opioid system?

Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010) · Psychological Review

Personality Disorders and PsychopathologyPersonality Traits and Psychology

Cited by 135

Enduring effects of psychological treatments for anxiety disorders: Meta-analysis of follow-up studies

Bandelow, B., Sagebiel, A., Belz, M., Görlich, Y., Michaelis, S., & Wedekind, D. (2018) · The British Journal of Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychotherapy Techniques and Applications

Cited by 70

Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease

Santos, J. R. F., Bauer, C., Schuchhardt, J., Wedekind, D., Waniek, K., Lachmann, I., Wiltfang, J., & Vogelgsang, J. (2019) · Journal of Neural Transmission

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 26